ERYP.PA Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (28 Jun 2023 @ 11:35):

ERYTECH Pharma S.A., a clinical-stage biopharmaceutical company, develops red blood cell-based therapeutics for cancer and orphan diseases in France and the United States...

Stats
Today's Volume	27 494.00
Average Volume	215 196
Market Cap	48.66M
EPS	€0 ( 2023-09-11 )
Last Dividend	€0 ( N/A )
Next Dividend	€0 ( N/A )
P/E	-80.10
ATR14	€0.0640 (7.99%)

Volume Correlation

Long: 0.27 (neutral)

Short: -0.60 (weak negative)

Signal:(41.547) Neutral

Erytech Pharma SA Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Erytech Pharma SA Correlation - Currency/Commodity

-0.18
( neutral )

-0.10
( neutral )

0.00
( neutral )

0.60
( weak )

-0.05
( neutral )

Erytech Pharma SA Financials

Annual	2022
Revenue:	€0
Gross Profit:	€0 (0.00 %)
EPS:	€-0.00740

Q4	2022
Revenue:	€0
Gross Profit:	€0 (0.00 %)
EPS:	€0.190

Q3	2022
Revenue:	€0
Gross Profit:	€0 (0.00 %)
EPS:	€-0.170

Q2	2022
Revenue:	€0
Gross Profit:	€0 (0.00 %)
EPS:	€0.350

Financial Reports:

No articles found.

Erytech Pharma SA

ERYTECH Pharma S.A., a clinical-stage biopharmaceutical company, develops red blood cell-based therapeutics for cancer and orphan diseases in France and the United States. Its lead product candidate is eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-?-lyase in red blood cells to target methionine cancers. The company was incorporated in 2004 and is headquartered in Lyon, France.